JPS6323186B2 - - Google Patents
Info
- Publication number
- JPS6323186B2 JPS6323186B2 JP57109097A JP10909782A JPS6323186B2 JP S6323186 B2 JPS6323186 B2 JP S6323186B2 JP 57109097 A JP57109097 A JP 57109097A JP 10909782 A JP10909782 A JP 10909782A JP S6323186 B2 JPS6323186 B2 JP S6323186B2
- Authority
- JP
- Japan
- Prior art keywords
- cyclopropane
- hydrochloride
- dimethylaminomethyl
- phenyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 15
- 125000005843 halogen group Chemical group 0.000 claims abstract description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract description 5
- 125000003277 amino group Chemical group 0.000 claims abstract description 4
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 150000007522 mineralic acids Chemical class 0.000 claims abstract description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 4
- 150000007524 organic acids Chemical class 0.000 claims abstract description 4
- 125000003118 aryl group Chemical group 0.000 claims abstract description 3
- 235000005985 organic acids Nutrition 0.000 claims abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 68
- 238000004519 manufacturing process Methods 0.000 claims description 18
- -1 1-phenyl-1-ethylaminocarbonyl- 2-dimethylaminomethyl-cyclopropane (Z) maleate Chemical compound 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 15
- HIJXSRHMNAUOKJ-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-phenylcyclopropane-1-carboxamide Chemical compound CN(C)CC1CC1(C(N)=O)C1=CC=CC=C1 HIJXSRHMNAUOKJ-UHFFFAOYSA-N 0.000 claims description 4
- LCTUOLQWOLBESS-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-[(dimethylamino)methyl]cyclopropane-1-carboxamide Chemical compound CN(C)CC1CC1(C(N)=O)C1=CC=CC=C1Cl LCTUOLQWOLBESS-UHFFFAOYSA-N 0.000 claims description 3
- VBXQDCQEXJOOHO-UHFFFAOYSA-N 1-(4-chlorophenyl)cyclopropane-1-carboxamide Chemical compound C=1C=C(Cl)C=CC=1C1(C(=O)N)CC1 VBXQDCQEXJOOHO-UHFFFAOYSA-N 0.000 claims description 3
- KGVHCQKNBHYQOK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-n,n-dimethyl-1-phenylcyclopropane-1-carboxamide Chemical compound CN(C)CC1CC1(C(=O)N(C)C)C1=CC=CC=C1 KGVHCQKNBHYQOK-UHFFFAOYSA-N 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 3
- GJJFMKBJSRMPLA-UHFFFAOYSA-N milnacipran Chemical compound C=1C=CC=CC=1C1(C(=O)N(CC)CC)CC1CN GJJFMKBJSRMPLA-UHFFFAOYSA-N 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- GOLWPWMGOGGGJF-UHFFFAOYSA-N [2-(morpholin-4-ylmethyl)-1-phenylcyclopropyl]-pyrrolidin-1-ylmethanone Chemical compound C1C(CN2CCOCC2)C1(C=1C=CC=CC=1)C(=O)N1CCCC1 GOLWPWMGOGGGJF-UHFFFAOYSA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 abstract description 3
- 229910052801 chlorine Inorganic materials 0.000 abstract description 2
- 125000001309 chloro group Chemical group Cl* 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000013078 crystal Substances 0.000 description 12
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 229910052740 iodine Inorganic materials 0.000 description 10
- 239000011630 iodine Substances 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000002329 infrared spectrum Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- MHLMRBVCMNDOCW-UHFFFAOYSA-N acetic acid;butan-1-ol;hydrate Chemical compound O.CC(O)=O.CCCCO MHLMRBVCMNDOCW-UHFFFAOYSA-N 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- OJHAHQJRQIOCFK-UHFFFAOYSA-N azane;chloroform;methanol Chemical compound N.OC.ClC(Cl)Cl OJHAHQJRQIOCFK-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- PDCWNMLMHGPHIC-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-phenylcyclopropane-1-carboxylic acid Chemical compound CN(C)CC1CC1(C(O)=O)C1=CC=CC=C1 PDCWNMLMHGPHIC-UHFFFAOYSA-N 0.000 description 2
- OGKPGFAXMGTFDJ-UHFFFAOYSA-N 4-(cyclopropylmethyl)morpholine Chemical compound C1COCCN1CC1CC1 OGKPGFAXMGTFDJ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- SLNPAVIBCNMVHG-UHFFFAOYSA-N cyclopropane;hydrazine Chemical compound NN.C1CC1 SLNPAVIBCNMVHG-UHFFFAOYSA-N 0.000 description 2
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- QKRSXNKJLFBCJR-UHFFFAOYSA-N ethyl 2-[(dimethylamino)methyl]-1-phenylcyclopropane-1-carboxylate Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CC1CN(C)C QKRSXNKJLFBCJR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
- LMRXDYSTKNCUDM-UHFFFAOYSA-N 2-(aminomethyl)-n,n-dimethyl-1-phenylcyclopropane-1-carboxamide Chemical compound C=1C=CC=CC=1C1(C(=O)N(C)C)CC1CN LMRXDYSTKNCUDM-UHFFFAOYSA-N 0.000 description 1
- PSMORJXEGALFGQ-UHFFFAOYSA-N 2-(hydroxymethyl)-1-phenylcyclopropane-1-carboxylic acid Chemical class OCC1CC1(C(O)=O)C1=CC=CC=C1 PSMORJXEGALFGQ-UHFFFAOYSA-N 0.000 description 1
- HVYIVKWZIMCZGG-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-phenylcyclopropane-1-carbonyl chloride Chemical compound CN(C)CC1CC1(C(Cl)=O)C1=CC=CC=C1 HVYIVKWZIMCZGG-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- NBMOUJYHHVJVEZ-UHFFFAOYSA-N ethyl 1-(3,4-dichlorophenyl)-2-[(dimethylamino)methyl]cyclopropane-1-carboxylate Chemical compound C=1C=C(Cl)C(Cl)=CC=1C1(C(=O)OCC)CC1CN(C)C NBMOUJYHHVJVEZ-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- VMVOTHRTTGEMKL-UHFFFAOYSA-N n,n-dimethyl-1-(2-phenylcyclopropyl)methanamine Chemical compound CN(C)CC1CC1C1=CC=CC=C1 VMVOTHRTTGEMKL-UHFFFAOYSA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8112312 | 1981-06-23 | ||
| FR8112312A FR2508035A1 (fr) | 1981-06-23 | 1981-06-23 | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS584752A JPS584752A (ja) | 1983-01-11 |
| JPS6323186B2 true JPS6323186B2 (member.php) | 1988-05-16 |
Family
ID=9259785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57109097A Granted JPS584752A (ja) | 1981-06-23 | 1982-06-23 | カルボキシアミド誘導体及びその製造法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4478836A (member.php) |
| EP (1) | EP0068999B1 (member.php) |
| JP (1) | JPS584752A (member.php) |
| AT (1) | ATE13422T1 (member.php) |
| AU (1) | AU550774B2 (member.php) |
| CA (1) | CA1202639A (member.php) |
| DE (1) | DE3263734D1 (member.php) |
| ES (1) | ES512842A0 (member.php) |
| FR (1) | FR2508035A1 (member.php) |
| LU (1) | LU90410I2 (member.php) |
| ZA (1) | ZA824453B (member.php) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006132307A1 (ja) | 2005-06-10 | 2006-12-14 | Pierre Fabre Medicament S.A. | 安定化されたミルナシプラン製剤 |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2581059B1 (fr) * | 1985-04-25 | 1988-04-22 | Pf Medicament | Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z) |
| FR2581060B1 (fr) * | 1985-04-25 | 1988-07-01 | Pf Medicament | Procede industriel d'obtention du midalcipran |
| EP0747348A4 (en) * | 1994-02-22 | 1999-07-07 | Asahi Chemical Ind | AMINOALKYLCYCLOPROPAN DERIVATIVES |
| CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
| EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| ATE192042T1 (de) * | 1995-08-16 | 2000-05-15 | Lilly Co Eli | Potenzierung von serotonin-wirkstoffresponz |
| FR2752732B1 (fr) * | 1996-08-28 | 1998-11-20 | Pf Medicament | Forme galenique a liberation prolongee de milnacipran |
| CN105712985A (zh) * | 2001-10-12 | 2016-06-29 | 阿泽范药品公司 | β-内酰胺后叶加压素V1a拮抗剂 |
| US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| US20040034101A1 (en) * | 2001-11-05 | 2004-02-19 | Cypress Bioscience, Inc. | Treatment and prevention of depression secondary to pain (DSP) |
| US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
| JP2005523334A (ja) * | 2002-04-24 | 2005-08-04 | サイプレス バイオサイエンス， インコーポレイテッド | ストレス関連障害を含む機能的身体障害の予防および処置 |
| CA2503381A1 (en) * | 2002-10-25 | 2004-05-13 | Collegium Pharmaceutical, Inc. | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| FR2851163B1 (fr) * | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
| WO2004075886A1 (fr) * | 2003-02-14 | 2004-09-10 | Pierre Fabre Medicament | Utilisation de l’enantiomere (1s, 2r) du milnacipran pour la preparation d’un medicament |
| JP2006523674A (ja) * | 2003-04-18 | 2006-10-19 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法 |
| CN1867549B (zh) * | 2003-08-15 | 2011-07-06 | H·隆德贝克有限公司 | 作为nk3受体拮抗剂的环丙基衍生物 |
| NZ544935A (en) | 2003-08-15 | 2009-08-28 | Lundbeck & Co As H | Cyclopropyl derivatives as NK3 receptor antagonists |
| ES2515092T3 (es) | 2003-12-11 | 2014-10-29 | Sunovion Pharmaceuticals Inc. | Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión |
| EP1737473A4 (en) * | 2004-04-19 | 2009-08-26 | Noven Therapeutics Llc | COMBINATIONS OF LITHIUM AND USES THEREOF |
| JP4418717B2 (ja) * | 2004-06-24 | 2010-02-24 | 住友化学株式会社 | （ｚ）−１−フェニル−１−ジエチルアミノカルボニル−２−アミノメチルシクロプロパン塩酸塩の製造方法 |
| CA2601709C (en) | 2005-03-22 | 2017-02-14 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids |
| US7368477B2 (en) * | 2005-04-22 | 2008-05-06 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof |
| CN101203216A (zh) * | 2005-04-22 | 2008-06-18 | 惠氏公司 | 二氢苯并呋喃衍生物及其用途 |
| EP1871755A1 (en) * | 2005-04-22 | 2008-01-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
| EP1904843A2 (en) | 2005-07-08 | 2008-04-02 | Braincells, Inc. | Methods for identifying agents and conditions that modulate neurogenesis |
| US8048874B2 (en) | 2005-07-19 | 2011-11-01 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists |
| US20090203750A1 (en) * | 2005-08-24 | 2009-08-13 | Alan Kozikowski | 5-HT2C Receptor Agonists as Anorectic Agents |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20080319083A1 (en) * | 2006-01-27 | 2008-12-25 | Asahi Kasei Pharma Corporation | Medicine for transnasal administration |
| EP1980271A4 (en) * | 2006-01-27 | 2012-04-25 | Asahi Kasei Pharma Corp | MEDICINE FOR TRANSNASAL ADMINISTRATION |
| FR2912057B1 (fr) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| RU2008135326A (ru) * | 2006-03-24 | 2010-04-27 | Вайет (Us) | Терапевтические композиции для лечения депрессии |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
| CA2662491A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| WO2008034032A2 (en) * | 2006-09-14 | 2008-03-20 | Azevan Pharmaceuticals, Inc. | Beta-lactam cannabinoid receptor modulators |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2008083204A2 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc. | Modulation of neurogenesis by melatoninergic ligands |
| EP2125017A2 (en) * | 2007-01-11 | 2009-12-02 | Braincells, Inc. | Modulation of neurogenesis with use of modafinil |
| WO2008104957A2 (en) * | 2007-02-28 | 2008-09-04 | Ranbaxy Laboratories Limited | Novel polymorphic forms of milnacipran hydrochloride |
| WO2009023820A1 (en) * | 2007-08-16 | 2009-02-19 | Cypress Biosciences, Inc. | Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination |
| US20090069431A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched milnacipran |
| EP2288345B1 (en) | 2008-04-18 | 2015-06-10 | University College Dublin National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| US20100092479A1 (en) * | 2008-08-18 | 2010-04-15 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| WO2010036773A1 (en) * | 2008-09-24 | 2010-04-01 | Concert Pharmaceuticals, Inc. | Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives |
| FR2941454B1 (fr) | 2009-01-29 | 2011-04-01 | Pf Medicament | Proced de synthese du (1s,2r)-milnacipran |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20100274050A1 (en) * | 2009-04-23 | 2010-10-28 | Glenmark Generics Limited | Solid milnacipran and process for the preparation of the same |
| US20100286260A1 (en) * | 2009-05-05 | 2010-11-11 | Forest Laboratories Holdings Ltd. | Milnacipran formulations |
| CA2775091A1 (en) | 2009-08-05 | 2011-02-10 | Lupin Limited | Controlled release pharmaceutical compositions of milnacipran |
| CA2779711C (en) * | 2009-11-06 | 2016-11-01 | Forest Laboratories Holding Limited | Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide |
| WO2011092065A1 (en) | 2010-01-29 | 2011-08-04 | Nicox S.A. | Nitric oxide releasing compounds for the treatment of neurophatic pain |
| CA2804001C (en) | 2010-07-01 | 2021-02-09 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
| US8916194B2 (en) | 2010-08-30 | 2014-12-23 | Lupin Limited | Controlled release pharmaceutical compositions of milnacipran |
| US20120289744A1 (en) | 2010-11-03 | 2012-11-15 | Arch Pharmalabs Limited | Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts |
| EP2699539B1 (en) | 2011-04-21 | 2019-03-06 | Emory University | Cyclopropyl derivatives and methods of use |
| WO2014009767A1 (en) | 2012-07-07 | 2014-01-16 | Micro Labs Limited | An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts |
| WO2014203277A2 (en) * | 2013-06-19 | 2014-12-24 | Msn Laboratories Private Limited | Process for the preparation of (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanearboxamide hydrochloride |
| IN2013MU03122A (member.php) | 2013-09-30 | 2015-07-17 | Cadila Healthcare Ltd | |
| CA2944211C (en) | 2014-03-28 | 2022-10-04 | Azevan Pharmaceuticals, Inc. | Compositions and methods for treating neurodegenerative diseases |
| KR102790657B1 (ko) | 2017-09-15 | 2025-04-02 | 아제반 파마슈티칼스, 인코퍼레이티드 | 뇌 손상을 치료하기 위한 조성물 및 방법 |
| JP7739256B2 (ja) | 2019-07-19 | 2025-09-16 | バイオエクセル セラピューティクス，インコーポレイテッド | 鎮静作用のないデクスメデトミジン治療レジメン |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA570688A (en) * | 1959-02-17 | E. Speeter Merrill | Antispasmodic substituted amines | |
| CA619080A (en) * | 1961-04-25 | The Upjohn Company | N-SUBSTITUTED-.alpha.-(TERTIARY-AMINOALKYL)-.alpha.-PHENYLACETAMIDES | |
| GB1415541A (en) | 1972-11-30 | 1975-11-26 | Hexachimie | 1-amino-methyl-2,2-diarylcyclopropanecarboxamide |
-
1981
- 1981-06-23 FR FR8112312A patent/FR2508035A1/fr active Granted
-
1982
- 1982-06-04 ES ES512842A patent/ES512842A0/es active Granted
- 1982-06-21 EP EP82401129A patent/EP0068999B1/fr not_active Expired
- 1982-06-21 AT AT82401129T patent/ATE13422T1/de active
- 1982-06-21 DE DE8282401129T patent/DE3263734D1/de not_active Expired
- 1982-06-22 AU AU85086/82A patent/AU550774B2/en not_active Expired
- 1982-06-22 US US06/390,810 patent/US4478836A/en not_active Expired - Lifetime
- 1982-06-22 CA CA000405651A patent/CA1202639A/fr not_active Expired
- 1982-06-23 ZA ZA824453A patent/ZA824453B/xx unknown
- 1982-06-23 JP JP57109097A patent/JPS584752A/ja active Granted
-
1999
- 1999-06-30 LU LU90410C patent/LU90410I2/fr unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006132307A1 (ja) | 2005-06-10 | 2006-12-14 | Pierre Fabre Medicament S.A. | 安定化されたミルナシプラン製剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS584752A (ja) | 1983-01-11 |
| ES8303293A1 (es) | 1983-03-01 |
| FR2508035A1 (fr) | 1982-12-24 |
| DE3263734D1 (en) | 1985-06-27 |
| LU90410I2 (fr) | 1999-08-31 |
| ZA824453B (en) | 1983-04-27 |
| CA1202639A (fr) | 1986-04-01 |
| ATE13422T1 (de) | 1985-06-15 |
| US4478836A (en) | 1984-10-23 |
| ES512842A0 (es) | 1983-03-01 |
| AU550774B2 (en) | 1986-04-10 |
| AU8508682A (en) | 1983-01-06 |
| EP0068999B1 (fr) | 1985-05-22 |
| EP0068999A1 (fr) | 1983-01-05 |
| FR2508035B1 (member.php) | 1984-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6323186B2 (member.php) | ||
| DE69204906T2 (de) | 2-Hydroxy-2-phenylethylaminderivate als Beta-3-adrenoceptor Agonisten. | |
| DE69023928T2 (de) | DIAMINVERBINDUNGEN UND ARZNEIMITTEL GEGEN CEREBRALE STöRUNGEN DIE DIESE ENTHALTEN. | |
| JP2003508380A (ja) | スルホニルカルボキサミド誘導体、その調製方法および医薬としてのその使用 | |
| JPS5832847A (ja) | （３−アミノプロポキシ）ビベンジル類 | |
| DE69622246T2 (de) | Neue Naphthamid-Derivate und ihre therapeutische Verwendung als D3-Rezeptor Agonisten | |
| HU193890B (en) | Process for preparing pyridazine derivatives active on central nervous system and pharmaceutics comprising the same | |
| SU1241986A3 (ru) | Способ получени производных бензамида,их гидрохлоридов или оптических изомеров | |
| DE68903531T2 (de) | Substituierte 1-(1h-imidazol-4-yl)alkyl-benzamide. | |
| JPH0764803B2 (ja) | カプサイシン誘導体 | |
| JPH02167279A (ja) | アポビンカミン酸誘導体 | |
| KR950006891B1 (ko) | 아미노 알코올의 제조방법 | |
| DE1931240A1 (de) | Aminoalkancarbonsaeuren | |
| JPH05504970A (ja) | 尿素誘導体類、それらの製造およびそれらを含有している薬用生成物 | |
| DK147854B (da) | Analogifremgangsmaade til fremstilling af n-(1-benzylpiperid-4-yl)-benzamider | |
| DE60001100T2 (de) | Benzamid-derivate und sie enthaltende medikamente | |
| JP2003508381A (ja) | 高脂血症の予防または治療用薬剤の製造のためのビススルホンアミドの使用 | |
| DE69622415T2 (de) | 12H-Dibenzo[d,g][1,3]dioxocin Derivate | |
| DE69521142T2 (de) | 6-methoxy-1h-benzotriazol-5-carboxamid-derivate, verfahren zur herstellung und diese enthaltende arzneimittel | |
| JPS6124388B2 (member.php) | ||
| JPH03209364A (ja) | １―（４―アミノフェニル）―２―ピペリジノプロパノン誘導体、製造方法、および治療学における用途 | |
| DE69717841T2 (de) | Substituierte n-arylmethylamino-cyclobuten-3,4-dion-derivate | |
| DE2322561A1 (de) | Trisubstituierte imidazole | |
| NO803835L (no) | Fremgangsmaate for fremstilling av n-substiuerte alfa-aminosyrer | |
| US3903165A (en) | Ethynylaryl amines and processes for their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080516 Year of fee payment: 20 |